Drugs / H107e/CAF®10b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06050356 | Mar 2024 → Dec 2026 expected | — | Statens Serum Institut | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H107e/CAF10b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06050356 ↗ |
| Modality | Vaccine | “This study tests the safety and vaccine-induced immune response of a new preventive TB vaccine called H107e/CAF®10b.” NCT06050356 ↗ |
| Route | Intramuscular | “Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29” NCT06050356 ↗ |